Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Skin cancer, melanoma
Stage/Subtype:  recurrent melanoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 111 for your search:
Start Over
Nivolumab and Ipilimumab with or without Sargramostim in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6141, NCI-2014-02674, NCT02339571
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients with High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E1609, NCI-2011-02649, CDR0000692568, ECOG-E1609, NCT01274338
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 103A-301, NCI-2012-01351, NCT01546571
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6134, NCI-2014-01747, NCT02224781
High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients with Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1404, NCI-2014-02676, NCT02506153
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP 01611, NCI-2014-01584, UPCC 01611, NCT01350401
Stereotactic Radiosurgery and Ipilimumab in Treating Patients With Stage IV Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 814393, NCI-2012-00749, UPCC 06611, NCT01497808
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162X2110, NCI-2012-00964, 2011-005875-17, NCT01543698
Decitabine and Vemurafenib in Treating Patients with Stage IV Melanoma Who Have a BRAF Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201304715, NCI-2014-00838, ML28604, NCT01876641
GSK2141795, Dabrafenib, and Trametinib in Treating Patients with Stage IIIC-IV Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1221, NCI-2013-01320, SWOG-S1221, NCT01902173
Ipilimumab and Dabrafenib in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: HCI68132, NCI-2014-02564, CA184-371, IDM, IRB # 68132, NCT02200562
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-03, NCI-2015-01413, NCT02413827
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B9991004, NCI-2015-02263, 2015-002552-27, JAVELIN MEDLEY, NCT02554812
Tumor Infiltrating Lymphocytes and High-Dose Aldesleukin with or without Autologous Dendritic Cells in Treating Patients with Metastatic Melanoma
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: 2004-0069, NCI-2012-01368, NCT00338377
Gene Therapy and Vaccine Therapy after a Conditioning Regimen in Treating Patients with Stage IIIC-IV Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 08-02-020, NCI-2010-00229, 0802-901, 10-001212, 1600, 53.08.0-h, 53.0B.0·h, MART-1 F5 TCR, OB02·901, NCT00910650
Pazopanib Hydrochloride and Paclitaxel as First-Line Therapy in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UCI 09-53, NCI-2010-00748, 11721, GW786034, PZP113567, NCT01107665
Aldesleukin with or without Ziv-Aflibercept in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: Over 16
Trial IDs: PHII-107, NCI-2011-02498, CDR0000690654, CHNMC-PHII-107, 8628, NCT01258855
Ipilimumab and Palliative Radiation Therapy in Treating Patients with Stage IV Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MEL0005, NCI-2011-03274, 21970, 5136, SU-08242011-8306, NCT01449279
Start Over